Another strategy uses heparanase-neutralizing monoclonal antibodies to target the interaction of heparanase with HS and has been tested in pre-clinical studies for various types of cancer, including myeloma, pancreatic carcinoma, and hepatocellular carcinoma [175]. This evidence concerns the gene HPSE and hepatocellular carcinoma.